<DOC>
	<DOCNO>NCT00816400</DOCNO>
	<brief_summary>Evaluate safety , tolerability tolerate maximum dose MEDI-575 adult subject advance solid tumor refractory standard therapy standard therapy exist .</brief_summary>
	<brief_title>A Dose Escalation , Dose Expansion Study Evaluate Safety , Tolerability , Antitumor Activity MEDI-575 , Subjects With Advanced Tumors .</brief_title>
	<detailed_description />
	<criteria>Histologically confirm advanced solid tumor curative standard therapy exist Karnofsky performance status ≥ 60 Life expectancy &gt; 12 week Adequate hematologic organ function Negative serum pregnancy test ( woman ) Two method birth control female participant childbearing potential male participant female partner childbearing potential Prior chemotherapy investigational treatment within 4 week study drug administration Prior biological immunological treatment within 6 week study drug administration Concurrent therapy cancer Major surgery within four week minor surgery within two week study drug administration History diabetes current treatment diabetes New York Heart Association ≥ Grade 2 congestive heart failure History myocardial infarction , unstable angina , transient ischemic attack stroke within previous 6 month prior study entry History invasive malignancy within 5 year ( exception cervical carcinoma situ , nonmelanomatous carcinoma skin ductal carcinoma situ breast surgically cure ) Significant active infection Known brain metastasis Pregnancy lactation plan become pregnant study Clinically significant abnormality ECG</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
</DOC>